Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTDamilola EsebameThu, August 13, 2026 at 12:17 AM GMT+2 5 min readAmerican seniors pay dramatically more for brand-name prescription drugs than patients in 19 comparable countries, and the gap keeps widening each year.AARP published a new report examining 25 top-selling brand-name drugs that account for more than $100 billion in annual Medicare spending.The findings arrive at a critical moment, with a federal subsidy program ending after 2026 that currently holds down premiums for standalone Medicare drug plans.Together, the pricing data and the subsidy expiration create financial pressure on roughly 25 million Americans enrolled in Medicare Part D coverage.The report strengthens the case for drug price negotiation, a policy that began producing results in 2026 with the first ten Medicare-negotiated medications.For retirees and those approaching Medicare eligibility, understanding both the pricing landscape and the coming premium changes will shape enrollment decisions this fall.U.S. prices for the 25 brand-name drugs in the study climbed 81% on average after their initial market launch,